With the creation of a Global Specialty Medicines group and the appointment of Rob Koremans as its president and CEO, specialty medicines will for the first time have a champion on Teva Pharmaceutical Industries Ltd.'s executive committee.

The group will help inform global product development at its earliest stages, which should translate into faster global launches of branded specialty medicines than Teva has achieved in the past, Koremans told BioCentury.